| Vol. 9.06 – 17 February, 2021 |
| |
|
|
| Scientists defined correlates of protection of neutralizing human monoclonal antibodies in SARS-CoV-2-infected animals. [Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators longitudinally assessed circulating proteins as well as 188 surface protein markers, transcriptome, and T-cell receptor sequence simultaneously in single peripheral immune cells from COVID-19 patients. [Cell] |
|
|
|
| The authors characterized and further evaluated the recently identified human monoclonal MD65 antibody for its ability to provide protection against a lethal SARS-CoV-2 infection of K18-hACE2 transgenic mice. [Nature Communications] |
|
|
|
| Researchers provide critical evidence that IgG, NAb, and T cell responses persisted in the majority of patients for at least three to four months after infection. [Nature Communications] |
|
|
|
| Investigators applied human induced pluripotent stem cell-based models and CRISPR-engineering to explore the host genetics of SARS-CoV-2. [Stem Cell Reports] |
|
|
|
| The authors observed that human PSC-cardiomyocytes (hPSC-CMs) expressed the viral receptor ACE2 and other viral processing factors, and that SARS-CoV-2 readily infected and replicated within hPSC-CMs, resulting in rapid cell death. [Stem Cell Reports] |
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists elucidated crystal structures, binding affinities and kinetics, and in vivo protection of eight anti-NANP antibodies derived from an RTS,S Phase IIa trial and encoded by three different heavy-chain germline genes. [Nature Communications] |
|
|
|
| Investigators hypothesized ICI resistance mutations in the IFNγ pathway would simultaneously render melanomas susceptible to oncolytic virus therapy. [Clinical Cancer Research] |
|
|
|
| The authors generated a Zika virus mutant, ZE4B-36, which combined mutations in both E glycosylation and NS4B P36. [npj Vaccines] |
|
|
|
| Researchers hypothesized that HIV induced the basal stem/progenitor cells to express inflammatory mediators that contributed to the pathogenesis of emphysema. [Scientific Reports] |
|
|
|
| Investigators collected alveolar macrophages by bronchoscopy performed in HIV-infected, antiretroviral therapy-naive and uninfected subjects. [Scientific Reports] |
|
|
|
|
| Scientists provide a conceptual framework for the interaction of the human innate immune system with SARS-CoV-2 to link the clinical observations with experimental findings that have been made during the first year of the pandemic. [Cell] |
|
|
|
| The author provides an overview of the current state of knowledge of the biology of these bacteria and their interactions with host cells, with a focus on pathogenic species or those that are otherwise important for human health. [Nature Reviews Microbiology] |
|
|
|
|
| Open Orphan plc announced the world’s first COVID-19 characterization study has received approval from a specially convened Research Ethics Committee. [Open Orphan plc (BusinessWire, Inc)] |
|
|
|
| SCYNEXIS, Inc. and Hansoh Pharmaceutical Group Company Limited announced a strategic partnership and license agreement for the development and commercialization of Ibrexafungerp for the Greater China region. [SCYNEXIS, Inc. (BusinessWire, Inc)] |
|
|
|
| ImmunityBio, Inc. and NantKwest, Inc. announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. [ImmunityBio, Inc. (BusinessWire, Inc)] |
|
|
|
| Takeda Pharmaceutical Company Limited announced new, late-breaking Phase III data from the TAK-620-303 trial, for the investigational drug TAK-620 which met its primary endpoint of superiority compared to conventional antiviral therapies in transplant recipients with refractory, with or without resistance, cytomegalovirus infection/disease. [Takeda Pharmaceutical Company Limited (BusinessWire, Inc)] |
|
|
|
|
| March 1 – 2, 2021 Virtual |
|
|
|
|
|
| University of California Merced – Merced, California, United States |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| Helmholtz Centre for Infection Research – Würzburg, Germany |
|
|
|
| NCCR AntiResist – Basel, Switzerland |
|
|
|
| UT Health Science Center at Tyler – Tyler, Texas, United States |
|
|
|
|